For the year ending 2025-12-31, LYEL has $340,052K in assets. $91,850K in debts. $60,181K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 60,181 | |||
| Marketable securities | 187,039 | |||
| Prepaid expenses and other current assets | 13,719 | |||
| Total current assets | 260,939 | |||
| Restricted cash | 1,585 | |||
| Marketable securities, non-current | 0 | |||
| Other investments | 19,000 | |||
| Property and equipment, net | 34,771 | |||
| Operating lease right-of-useassets | 18,871 | |||
| Othernon-currentassets | 4,886 | |||
| Total assets | 340,052 | |||
| Accounts payable | 2,893 | |||
| Accrued liabilities and other current liabilities | 46,519 | |||
| Contingent consideration payable | 0 | |||
| Total current liabilities | 49,412 | |||
| Operating lease liabilities, non-current | 41,921 | |||
| Othernon-currentliabilities | 517 | |||
| Total liabilities | 91,850 | |||
| Common stock, 0.0001 par value 500,000 shares authorized at december31, 2025 and 2024, respectively 21,251 and 14,744 shares issued and outstanding at december31, 2025 and 2024, respectively | 2 | |||
| Additionalpaid-incapital | 1,867,512 | |||
| Accumulated other comprehensive income | 242 | |||
| Accumulated deficit | -1,619,554 | |||
| Total stockholders equity | 248,202 | |||
| Total liabilities and stockholders equity | 340,052 | |||
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)